豚ワクチンの世界市場規模：適応疾患別、技術別、地域範囲別、予測

豚ワクチンの市場規模と予測

豚ワクチンの市場規模は、2024年に21億9,000万米ドルと評価され、2026年から2032年にかけてCAGR 7.27%で成長し、2032年には38億3,000万米ドルに達すると予測されています。

世界の豚ワクチン市場の成長を後押ししている主な要因としては、豚肉消費量の増加と豚疾病の蔓延が挙げられます。また、世界中の政府が動物医療分野への支出を増やしています。豚ワクチンの世界市場レポートでは、予測期間における市場の全体的な評価を提供します。本レポートは、様々なセグメントと、市場で重要な役割を果たしている動向や要因の分析から構成されています。

豚ワクチンの世界市場定義

ワクチンは動物と人間の両方にとって最も重要な疾病予防手段です。ワクチン接種は、多くの風土病の蔓延を防ぎ、動物の福祉を守るための動物用医薬品の恩恵とみなされています。豚のワクチンは、豚の健康を改善し、ウイルスや細菌、その他の病原体から豚を守ることで、致命的な病気から豚を守るために臨床的に使用されています。

このような病気には、豚生殖・呼吸器ウイルス（PRRSV）、豚インフルエンザ、豚サーコウイルス関連病（PCVAD）などがあります。また、致命的なウイルスから豚を保護する全体的な効率を向上させながら、人間が消費する高品質の肉の収量を増加させる。北米や欧州では、コレラや口蹄疫のような多くの疾病が、これらのワクチンを使用することで大幅に排除されています。

世界の豚ワクチン市場概要

豚肉消費量の増加は、世界の豚ワクチン市場の重要な促進要因です。この消費量の増加により、豚が罹患し人間に脅威を与える可能性のあるあらゆる疾病から豚集団を守る必要性が高まると予想されます。そのため、様々な豚の病気を予防する豚ワクチンの需要が高まると予想されます。

また、豚インフルエンザ、豚流行性下痢（PED）、豚繁殖・呼吸器症候群（PRRS）の発生件数が世界的に増加していることから、子豚への早期ワクチン接種が増加しています。その他の重要な促進要因としては、豚の病気に関する啓発プログラムの増加や、動物医療に対する政府資金の増加が挙げられます。

技術の進歩と研究開発の拡大は、世界の豚ワクチン市場の成長につながる新たな収益機会を提供すると期待されています。混合ワクチンの生産は成長の好機となります。また、DNAワクチンにより、農業従事者は自分の農場で病気のない豚を生産することができます。このように、市場には十分な成長機会があります。しかし、ワクチンの維持、輸送、保管にかかる高いコストのようないくつかの阻害要因があり、これが豚ワクチン産業の成長に悪影響を及ぼすと予想されています。

目次

第1章 世界の豚ワクチン市場の導入

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 世界の豚ワクチン市場展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル

第5章 ブタ用ワクチンの世界市場：適応疾患別

• イントロダクション
• 豚インフルエンザ
• 下痢
• 関節炎
• 豚生殖・呼吸器症候群
• 豚サーコウイルス関連疾患
• その他

第6章 豚ワクチンの世界市場：技術別

• イントロダクション
• 不活化ワクチン
• 弱毒生ワクチン
• 組み換えワクチン
• DNAワクチン
• その他

第7章 世界の豚ワクチン市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他の欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他のアジア太平洋
• 世界のその他の地域
  • 中東・アフリカ
  • 南米

第8章 世界の豚ワクチン市場の競合情勢

• 概要
• 各社の市場ランキング
• 主な開発戦略

第9章 企業プロファイル

• Merial
• Zoetis Inc.
• Intervet Inc.
• Vetoquinol
• Bayer AG
• IDT Biologika GmbH
• HIPRA
• Ceva Sante Animale
• Elanco
• Arko Laboratories Ltd

第10章 付録

• 関連調査

Porcine Vaccine Market Size And Forecast

Porcine Vaccine Market size was valued at USD 2.19 Billion in 2024 and is projected to reach USD 3.83 Billion by 2032, growing at a CAGR of 7.27% from 2026 to 2032.

Some of the key contributing factors propelling the growth of the Global Porcine Vaccine Market are an increase in pork consumption and a rise in the prevalence of swine diseases. Also, governments across the globe are spending higher in the field of animal health care. The Global Porcine Vaccine Market report provides a holistic evaluation of the market for the forecast period. The report comprises various segments as well as an analysis of the trends and factors that are playing a substantial role in the market.

Global Porcine Vaccine Market Definition

Vaccines are the most important disease prevention tools for both animals and humans. Vaccination is regarded as a boon in veterinary pharmaceuticals for preserving animal welfare by avoiding the spread of many endemic diseases. Porcine vaccines are used clinically to improve swine health and protect them from deadly diseases by guarding them against viruses, bacteria, and other pathogens.

Such diseases include porcine reproductive and respiratory virus (PRRSV), swine influenza, and porcine circovirus-associated disease (PCVAD) among others. It also increases the yield of high-quality meat for human consumption while improving overall efficiency in protecting pigs from deadly viruses. In North America and Europe, many diseases like cholera, foot & mouth disease have been significantly eliminated by using these vaccines.

Global Porcine Vaccine Market Overview

The increase in pork consumption is an important driver for the Global Porcine Vaccine Market. This increase in consumption is expected to result in a greater need to keep the swine population free of any disease that could affect them and pose a threat to humans. Thus the demand for swine vaccines that guards against various porcine diseases is expected to rise.

Also, higher instances of swine flu, porcine epidemic diarrhea (PED), and porcine reproductive and respiratory syndrome (PRRS) in farms worldwide have led to an increase in early vaccination of piglets. Other important drivers are the increasing number of awareness programs about porcine diseases and increased government funding for animal health care.

Technological advancements and growing research and development are expected to provide new profitable opportunities leading to the growth of the Global Porcine Vaccine Market. Combined vaccine production gives a good opportunity for growth. Also, DNA vaccines allow agriculture farmers to produce disease-free swine on their farms. Thus, there are ample growth opportunities for the market. However, there are some restraints like the high cost of maintaining, transportation, and storage of vaccines that are expected to adversely impact the growth of the Porcine Vaccine industry.

Global Porcine Vaccine Market Segmentation Analysis

The Global Porcine Vaccine Market is segmented on the basis of Disease Indication, Technology, And Geography.

Porcine Vaccine Market, By Disease Indication

• Swine Influenza
• Diarrhea
• Arthritis
• Porcine Reproductive and Respiratory Syndrome
• Porcine Circovirus Associated Disease
• Others

Based on Disease Indication, The market is segmented into Swine Influenza, Diarrhea, Arthritis, Porcine Reproductive and Respiratory Syndrome, Porcine Circovirus Associated Disease, and Others. Diarrhea and swine influenza dominate the Global Porcine Vaccine Market owing to factors like changes in climate including global warming and overfeeding of protein diet among others.

Porcine Vaccine Market, By Technology

• Inactivated vaccines
• Live attenuated vaccines
• Recombinant vaccines
• DNA vaccines
• Others

Based on Technology, The market is segmented into Inactivated vaccines, Live attenuated vaccines, Recombinant vaccines, DNA vaccines, and Others. Inactivated vaccines are leading the market. DNA vaccines are gaining popularity in veterinary hospitals as they have several advantages over live attenuated vaccines and inactivated vaccines.

Porcine Vaccine Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world
• On the basis of Geography, The Global Porcine Vaccine Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America leads the Global Porcine Vaccine Market by geography due to the rise in pork consumption, increasing instances of various swine diseases, and higher per-capita animal healthcare expenditure in the United States. The Asia Pacific region will have good growth due to increasing awareness about porcine health, and growing advancements in the field of biotechnology.

Key Players

The "Global Porcine Vaccine Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Bayer AG, Hipra, Ceva Sante Animale, Eli Lilly and Company, Merck & Co. Inc., Sanofi S.A, Zoetis Inc., Arko Laboratories Ltd, and Vetoquinol. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

• On August 5, 2021 Bayer AG announced the acquisition of Vividion Therapeutics, Inc. (Vividion), a US-based biopharmaceutical company that specializes in novel detection technology to unlock high-volume, uncontrolled traditional therapies with specific therapies. The Vividion platform is capable of producing a wide range of therapeutic approaches to small molecules in all directions, with an initial focus on oncology and immunology. Vividion's leading programs include a wide range of oncology specification and immunology guidelines, with ongoing efforts to counteract NRF2 antagonism for the possible treatment of NRF2 cancer, and NRF2 activists for various inflammatory diseases such as acute intestinal disease - among other treatment programs.
• On February 18, 2021 Philippe Mauguin, INRAE chief executive officer and Drs. Marc Prikazsky, Chairman and CEO of Ceva Sante Animale (Ceva), signed a first-round agreement aimed at consolidating their animal health partnerships. This signature comes in the context of Covid-19 disease and the outbreak of bird flu in France. It affirms the shared goal of working together for the "One Health", global health concept at animal crossroads, human and environmental health and, in particular, to prevent infectious diseases from the environment and to improve animal welfare.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL PORCINE VACCINE MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL PORCINE VACCINE MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model

5 GLOBAL PORCINE VACCINE MARKET, BY DISEASE INDICATION

• 5.1 Introduction
• 5.2 Swine Influenza
• 5.3 Diarrhea
• 5.4 Arthritis
• 5.5 Porcine Reproductive and Respiratory Syndrome
• 5.6 Porcine Circovirus Associated Disease
• 5.7 Others

6 GLOBAL PORCINE VACCINE MARKET, BY TECHNOLOGY

• 6.1 Introduction
• 6.2 Inactivated vaccines
• 6.3 Live attenuated vaccines
• 6.4 Recombinant vaccines
• 6.5 DNA vaccines
• 6.6 Others

7 GLOBAL PORCINE VACCINE MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Rest of the World
  • 7.5.1 Middle East and Africa
  • 7.5.2 South America

8 GLOBAL PORCINE VACCINE MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Development Strategies

9 COMPANY PROFILES

• 9.1 Merial
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 Zoetis Inc.
  • 9.2.1 Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Outlook
  • 9.2.4 Key Developments
• 9.3 Intervet Inc.
  • 9.3.1 Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Outlook
  • 9.3.4 Key Developments
• 9.4 Vetoquinol
  • 9.4.1 Overview
  • 9.4.2 Financial Performance
  • 9.4.3 Product Outlook
  • 9.4.4 Key Developments
• 9.5 Bayer AG
  • 9.5.1 Overview
  • 9.5.2 Financial Performance
  • 9.5.3 Product Outlook
  • 9.5.4 Key Developments
• 9.6 IDT Biologika GmbH
  • 9.6.1 Overview
  • 9.6.2 Financial Performance
  • 9.6.3 Product Outlook
  • 9.6.4 Key Developments
• 9.7 HIPRA
  • 9.7.1 Overview
  • 9.7.2 Financial Performance
  • 9.7.3 Product Outlook
  • 9.7.4 Key Developments
• 9.8 Ceva Sante Animale
  • 9.8.1 Overview
  • 9.8.2 Financial Performance
  • 9.8.3 Product Outlook
  • 9.8.4 Key Developments
• 9.9 Elanco
  • 9.9.1 Overview
  • 9.9.2 Financial Performance
  • 9.9.3 Product Outlook
  • 9.9.4 Key Developments
• 9.10 Arko Laboratories Ltd
  • 9.10.1 Overview
  • 9.10.2 Financial Performance
  • 9.10.3 Product Outlook
  • 9.10.4 Key Developments

10 APPENDIX

• 10.1 Related Research